Second-Line Chemotherapy in Recurrent Clear Cell Ovarian Cancer: Results from the Multicenter Italian Trials in Ovarian Cancer (MITO-9)

Publisher： Karger

E-ISSN： 1423-0232|86|5-6|351-358

ISSN： 0030-2414

Source： Oncology, Vol.86, Iss.5-6, 2014-06, pp. : 351-358

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemcitabine Combined with Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Patients with Advanced Ovarian Cancer Refractory or Resistant to Platinum and Taxane

By  

Oncology, Vol. 67, Iss. 5-6, 2005-02 ,pp. : 376-381

Karger

Access to resources Recommend Favorite

Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study

By  

Oncology, Vol. 80, Iss. 3-4, 2011-07 ,pp. : 238-246

Karger

Access to resources Recommend Favorite

Second-Line Chemotherapy in Advanced Bladder Cancer

By  

Urologia Internationalis, Vol. 64, Iss. 2, 2000-05 ,pp. : 61-69

Karger

Access to resources Recommend Favorite

Phase 2 Trial of Interferon-Beta as Second-Line Treatment of Ovarian Cancer, Fallopian Tube Cancer, or Primary Carcinoma of the Peritoneum

By  

Oncology, Vol. 66, Iss. 5, 2004-09 ,pp. : 343-346

Karger

Access to resources Recommend Favorite

Surgery for recurrent ovarian cancer

By Heitz Florian   du Bois Andreas   Kurzeder Christian   Pfisterer Jacobus   Barinoff Jana   Grabowski Jacek   Hilpert Felix   Mahner Sven   Harter Philipp  

Women's Health, Vol. 7, Iss. 5, 2011-09 ,pp. : 529-535

Future Medicine

Access to resources Recommend Favorite